Baillie Gifford & Co. Sells 20,097 Shares of RxSight, Inc. (NASDAQ:RXST)

Baillie Gifford & Co. decreased its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 4.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 398,907 shares of the company's stock after selling 20,097 shares during the quarter. Baillie Gifford & Co. owned approximately 0.99% of RxSight worth $13,714,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC raised its position in shares of RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock valued at $29,000 after purchasing an additional 521 shares during the period. Quarry LP raised its position in shares of RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company's stock valued at $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of RxSight in the third quarter valued at approximately $34,000. Harbor Investment Advisory LLC bought a new position in shares of RxSight in the fourth quarter valued at approximately $52,000. Finally, KBC Group NV raised its position in shares of RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company's stock valued at $61,000 after purchasing an additional 479 shares during the period. Institutional investors own 78.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RXST. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price objective on the stock. Wells Fargo & Company lowered their price objective on shares of RxSight from $42.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. UBS Group began coverage on shares of RxSight in a research note on Friday, December 6th. They issued a "buy" rating and a $52.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $66.00 price objective on shares of RxSight in a research note on Monday, January 13th. Finally, Stifel Nicolaus lowered their price objective on shares of RxSight from $40.00 to $35.00 and set a "hold" rating on the stock in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $58.13.

Insiders Place Their Bets

In other RxSight news, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now owns 10,902 shares in the company, valued at $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction on Friday, November 29th. The stock was sold at an average price of $46.08, for a total transaction of $143,078.40. Following the sale, the insider now owns 42,246 shares in the company, valued at $1,946,695.68. This represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,506 shares of company stock worth $567,456 over the last 90 days. Corporate insiders own 9.36% of the company's stock.

RxSight Stock Down 2.4 %

RXST traded down $0.73 during trading on Friday, reaching $29.60. 526,195 shares of the company's stock were exchanged, compared to its average volume of 604,370. RxSight, Inc. has a fifty-two week low of $26.29 and a fifty-two week high of $66.54. The business has a 50 day moving average price of $33.14 and a 200 day moving average price of $43.81. The company has a market capitalization of $1.19 billion, a P/E ratio of -35.66 and a beta of 1.19.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.